As promised, President Trump has promptly abandoned the Trans-Pacific Partnership. What might this mean for biopharma?
Nixing the so-called TPP could spell trouble for the biopharmaceutical industry moving forward when it comes to market exclusivity, according to Kevin Noonan, a partner at Chicago-based intellectual property law firm McDonnell Boehnen Hulbert & Berghoff.
About the Author Reprints
